Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases
Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases
Company Info
Company news
Thu, 29 Aug 2024 07:00:00 GMT
Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewswire
Thu, 07 Nov 2024 08:00:00 GMT
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Thu, 07 Nov 2024 08:00:00 GMT
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Wed, 18 Aug 2021 07:00:00 GMT
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases - Business Wire
Tue, 05 Nov 2024 08:00:00 GMT
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - StockTitan
Tue, 17 Sep 2024 07:00:00 GMT
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewswire
Thu, 27 Jun 2024 07:00:00 GMT
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi - GlobeNewswire
Tue, 30 Jul 2024 07:00:00 GMT
Vigil Presents Data on its Small Molecule TREM2 Agonist - GlobeNewswire
Mon, 07 Aug 2023 07:00:00 GMT
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer - GlobeNewswire
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.